



Sartorius completes acquisition of Novasep's chromatography equipment division

- An opportunity for Novasep's chromatography equipment division to accelerate its growth by joining an established leader in the sector
- A divestment aligned with Novasep's core strategy, focused on CDMO services for the pharmaceutical market

Lyon, France - February 8, 2022 - Novasep, a leading supplier of services and technologies for the life sciences industry, and Sartorius Stedim Biotech, a subgroup of the life science company Sartorius, announce today the completion as of February 7, 2022, of the sale of Novasep's chromatography equipment division to Sartorius, further to all relevant regulatory approvals having been obtained. The transaction had already been agreed upon at the beginning of 2021.

Novasep's chromatography equipment division comprises resin-based batch and intensified chromatography systems, and focuses on low & high pressure for small and large molecules such as monoclonal antibodies, oligonucleotides, peptides and insulin. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 employees concerned work mainly on Novasep's Pompey site in eastern France and some in the USA, China and India.

Since 2018, Novasep and Sartorius have been collaborating in the joint development of an optimized membrane-based, low-pressure chromatography system that processes larger molecules more productively.

This transaction is a major step for the development of the equipment business worldwide, based on the long-term expertise of Novasep's employees and Sartorius' strong position on this market segment.

"This achievement strengthens our relationship with the Sartorius team and represents a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership", says Dr. Michel Spagnol, President & CEO of Novasep. *"Furthermore, this announcement is aligned with Novasep's current strategy, which is to prioritize its core business on API CDMO services for the pharmaceutical market."*

Novasep will continue to offer CDMO development & manufacturing services for the pharmaceutical and biopharmaceutical markets, based on chromatography, which remains a core technology.

About Novasep

Novasep offers flexible [contract development & manufacturing \(CDMO\) solutions](#) for small molecule APIs & biopharmaceuticals to innovators. We propose a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record. We are a world leader in a number of specialized technologies including HPAPIs, ADCs, hazardous & cryogenic chemistry and industrial chromatography (batch and continuous).

Press contact

Justine Reynaud

Press Relations & Web Manager

+33 (0)4 37 28 20 52

press@novasep.com